4basebio PLC on Thursday noted a ‘key milestone’ with its client, which is progressing into a phase one clinical trial.

4basebio is a Cambridge, England-based life-science tech company with proprietary technologies in the field of DNA synthesis.

4basebio said its client Helix Nanotechnologies Inc has received HREC approval to progress into a phase one clinical trial in Australia with HN-0001, an mRNA vaccine generated from 4basebio‘s synthetic DNA, opDNA.

It added that it will continue to support HelixNano with the manufacture of GMP synthetic DNA planned for later in 2024.

Amy Walker, vice president of Research & Business Development, commented: ‘It’s been a pleasure to work with such an innovative company on their journey to the clinic and we are delighted to see an mRNA vaccine manufactured using 4basebio DNA progressing into patients; this represents another significant milestone for the company.’

‘4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials; we are of course very pleased to be supporting our clients in their clinical programs.’

Shares in 4basebio were down 0.9% to 966.00 pence each in London on Thursday afternoon.

Copyright 2024 Alliance News Ltd. All Rights Reserved.